XOMA Corp. has restructured in an effort to focus on gevokizumab (XOMA 052) opportunities and the company’s antibody discovery and development capabilities. XOMA plans to eliminate 84 positions, or 34% of personnel, with 50 positions to be eliminated immediately and the remainder by the end of 1Q12. The company plans to use CMOs for Phase III and commercial production and will eliminate internal research functions that can be obtained through the use of contract service providers. XOMA an...